Chemed (NYSE:CHE) Updates FY 2024 Earnings Guidance

Chemed (NYSE:CHE) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 23.000-23.150 for the period, compared to the consensus estimate of 23.580. The company issued revenue guidance of -. Chemed also updated its FY24 guidance to $23.00-$23.15 EPS.

Chemed Stock Down 0.9 %

CHE stock traded down $4.66 during midday trading on Friday, hitting $535.58. The company’s stock had a trading volume of 102,188 shares, compared to its average volume of 84,744. Chemed has a 52-week low of $525.36 and a 52-week high of $654.62. The firm has a 50-day simple moving average of $586.09 and a 200-day simple moving average of $568.84. The firm has a market capitalization of $8.06 billion, a P/E ratio of 27.32, a PEG ratio of 2.18 and a beta of 0.44.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing analysts’ consensus estimates of $5.76 by ($0.12). Chemed had a net margin of 12.69% and a return on equity of 27.86%. The firm had revenue of $606.18 million during the quarter, compared to analyst estimates of $612.22 million. During the same quarter in the previous year, the business posted $5.32 earnings per share. Chemed’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, sell-side analysts expect that Chemed will post 21.77 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Andrea R. Lindell sold 831 shares of Chemed stock in a transaction on Friday, August 16th. The shares were sold at an average price of $571.51, for a total transaction of $474,924.81. Following the sale, the director now directly owns 5,725 shares in the company, valued at $3,271,894.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Chemed news, Director Andrea R. Lindell sold 831 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $571.51, for a total value of $474,924.81. Following the sale, the director now owns 5,725 shares of the company’s stock, valued at $3,271,894.75. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nicholas Michael Westfall sold 1,713 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $569.35, for a total transaction of $975,296.55. Following the completion of the sale, the executive vice president now directly owns 6,109 shares in the company, valued at $3,478,159.15. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,144 shares of company stock worth $4,141,679 in the last ninety days. 3.32% of the stock is owned by corporate insiders.

About Chemed

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.